Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Stoke Therapeutics Inc (STOK)

Stoke Therapeutics Inc (STOK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 707,803
  • Shares Outstanding, K 52,121
  • Annual Sales, $ 8,780 K
  • Annual Income, $ -104,700 K
  • 60-Month Beta 0.87
  • Price/Sales 80.91
  • Price/Cash Flow N/A
  • Price/Book 5.06
Trade STOK with:

Options Overview Details

View History
  • Implied Volatility 107.88% ( +14.60%)
  • Historical Volatility 66.83%
  • IV Percentile 62%
  • IV Rank 24.34%
  • IV High 284.83% on 07/20/23
  • IV Low 50.95% on 11/13/23
  • Put/Call Vol Ratio 999.99
  • Today's Volume 1
  • Volume Avg (30-Day) 20
  • Put/Call OI Ratio 0.37
  • Today's Open Interest 936
  • Open Int (30-Day) 902

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.55
  • Number of Estimates 5
  • High Estimate -0.45
  • Low Estimate -0.63
  • Prior Year -0.69
  • Growth Rate Est. (year over year) +20.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.24 +10.95%
on 07/05/24
15.26 -11.01%
on 06/20/24
-1.49 (-9.89%)
since 06/18/24
3-Month
10.90 +24.59%
on 04/22/24
17.58 -22.75%
on 06/13/24
+1.53 (+12.70%)
since 04/19/24
52-Week
3.35 +305.37%
on 10/27/23
17.58 -22.75%
on 06/13/24
+2.23 (+19.65%)
since 07/19/23

Most Recent Stories

More News
Stocks Inch Higher After February's US Durable Goods Orders Released

Stocks are slightly up this morning as market participants reacted to February's US Durable Goods Report.

$SPX : 5,505.00 (-0.71%)
SPY : 548.99 (-0.66%)
$DOWI : 40,287.53 (-0.93%)
DIA : 402.95 (-0.88%)
$IUXX : 19,522.62 (-0.93%)
QQQ : 475.24 (-0.89%)
TTWO : 150.32 (+0.01%)
UAL : 47.93 (+3.32%)
MCD : 257.28 (-0.86%)
DIS : 95.74 (-1.08%)
OCDO.LN : 378.100 (-3.67%)
STOK : 13.58 (-0.37%)
This Under-the-Radar Growth Stock Could Soar by 277%, According to Wall Street

This small-cap biotech might be a hidden gem.

ACAD : 17.75 (-1.39%)
STOK : 13.58 (-0.37%)
Why Shares of Stoke Therapeutics Plummeted Tuesday

The company's shares fell after it released early trial results on its lead therapy.

STOK : 13.58 (-0.37%)
Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today reported...

STOK : 13.58 (-0.37%)
Stoke Therapeutics to Present at the BofA Securities Health Care Conference

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced...

STOK : 13.58 (-0.37%)
Stoke Therapeutics Receives Authorization to Initiate a Phase 1/2 Study of STK-002 for Autosomal Dominant Optic Atrophy (ADOA) in the United Kingdom

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced...

STOK : 13.58 (-0.37%)
Stoke Therapeutics Announces That FDA Will Allow the Administration of a Higher Single Dose of STK-001 (70mg) in the Ongoing Phase 1/2a MONARCH Study of Children and Adolescents with Dravet Syndrome

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced...

STOK : 13.58 (-0.37%)
Stoke Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today reported...

STOK : 13.58 (-0.37%)
Stoke Therapeutics to Participate at Upcoming March Investor Conferences

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced...

STOK : 13.58 (-0.37%)
Stoke Therapeutics to Present at the SVB Securities Global Biopharma Conference

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced...

STOK : 13.58 (-0.37%)

Business Summary

Stoke Therapeutics Inc. is a biopharmaceutical company. It develops antisense oligonucleotide medicines to treat genetic diseases. The company's product candidate consists of STK-001 which is to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics Inc. is based in Bedford,...

See More

Key Turning Points

3rd Resistance Point 14.27
2nd Resistance Point 14.09
1st Resistance Point 13.84
Last Price 13.58
1st Support Level 13.41
2nd Support Level 13.23
3rd Support Level 12.98

See More

52-Week High 17.58
Last Price 13.58
Fibonacci 61.8% 12.14
Fibonacci 50% 10.47
Fibonacci 38.2% 8.79
52-Week Low 3.35

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar